Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial

Hellemond, Irene E G van; Smorenburg, Carolien H.; Peer, Petronella G. M.; Swinkels, Astrid; Seynaeve, Caroline; Sangen, M.J.C. van der; Kroep, Judith R.; Graaf, Hiltje de; Honkoop, Aafke H.; Erdkamp, Frans; Berkmortel, Franchette W P J van den; Roos, W; Linn, Sabine C.; Imholz, Alexander L.T.; Boer, Maaike de; Tjan‐Heijnen, Vivianne C. G.

doi:10.1007/s10549-020-05567-9

Cited by 5 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A sub-study of the DATA trial was published by Van Hellemond et al 17 in 2020, focusing on breast cancer outcomes with bone mineral density and bisphosphonate use. It was concluded that 49.5% of patients had osteopenia while 12.3% had osteoporosis.…”

Section: Discussionmentioning

confidence: 99%

Osteoporosis/Osteopenia in Post-Menopausal Breast Cancer Patients Receiving Hormonal Therapy

Khattak

Ahmad

Nadeem

et al. 2022

PAFMJ

View full text Add to dashboard Cite

Objective: To analyze the presence of osteoporosis and osteopenia in post-menopausal breast cancer patients receiving hormonal therapy. Study Design: Comparative Cross-sectional Study. Place and Duration of Study: Oncology Department, Combined Military Hospital Rawalpindi Pakistan, from Dec 2020 to May 2021. Methodology: This study was conducted on 200 post-menopausal female breast cancer patients who had been taking Aromatase inhibitors for more than six months. All the study participants underwent a dual-energy X-ray absorptiometry (DEXA) scan to measure bone mineral density. As a result, they were classified as having osteoporosis or osteopenia based on bone mineral density. In addition, age, duration of therapy, tumour stage and molecular subtypes of breast cancer were correlated with the presence of osteopenia/osteoporosis in the study participants. Results: A total of 200 post-menopausal patients with breast cancer using hormonal therapy for more than six months were included in the final analysis. The mean age of the patients was 56.331 ± 6.744 years. In addition, 55 (22.5%) patients had normal bone mineral density, 92 (46%) had osteopenia, while 53 (26.5%) had osteoporosis on a dual-energy X-ray absorp- tiometry (DEXA) scan. Molecular subtypes of the tumour, the advancing age of patients and the long duration of hormonal therapy were statistically significantly associated with the presence of osteopenia/osteoporosis (p-value <0.05) in our study participants. Conclusion: Considerable number of post-menopausal patients with advanced breast cancer taking hormonal therapy showed the presence of osteopenia and osteoporosis. Molecular subtyping, the advanced age of patients and the long duration of hormonal therapy significantly predicted.........

show abstract

Section: Discussionmentioning

confidence: 99%

Osteoporosis/Osteopenia in Post-Menopausal Breast Cancer Patients Receiving Hormonal Therapy

Khattak

Ahmad

Nadeem

et al. 2022

PAFMJ

View full text Add to dashboard Cite

show abstract

“…van Hellemond et al (12) in 2018 studied the relevance between a reduced BMD and distant recurrence-free survival (DRFS) of breast cancer patients and evaluated the effect of bisphosphonates on DRFS. After 5 years of followup, Osteopenia and psteoporosis were not related to DRFS.…”

Section: Bisphosphonates Administration In Breast Cancer Patientsmentioning

confidence: 99%

“…MRONJ with a 3% to 5.3% prevalence among breast cancer patients has become a relevant and serious condition (10,11). van Hellemond et al (12) reported that no association was observed between reduction of bone mineral density (BMD) and distant recurrence-free survival. Neither did they observe an impact of bisphosphonates on distant recurrence-free survival.…”

mentioning

confidence: 99%

A Review of Literature on Updates of Bisphosphonates Administration, Cancer Biomarkers for Bisphosphonate Therapy, and Bisphosphonate-related Osteonecrosis of the Jaw in Breast Cancer

et al. 2021

View full text Add to dashboard Cite

Context: The emergence of bone health maintenance in breast cancer patients is known as an indispensable aspect in survival and morbidity improvement; therefore, bisphosphonates play a substantial role in the prevention/delaying of cancer treatment induced bone loss and skeletal-related events (SREs) in these patients, although this drug can cause necrosis of the jaw. In this article, we aimed at summarizing updated evidence on bisphosphonates administration, biomarkers representative of the efficacy of bisphosphonate therapy, and bisphosphonate-related osteonecrosis of the jaw (BRONJ) affection in patients involved in breast cancer. Methods: Associated published articles were searched for in EMBASE, MEDLINE, CDSR, PubMed, Google Scholar, and CINAHL, using the following keywords or, in the case of PubMed database, medical subject headings (MeSH): ‘Diphosphonate’, ‘osteonecrosis’, ‘breast cancer’, and ‘biomarker’ in the abstract or title, and was limited by "clinical trials, meta-analysis and randomized controlled trial” published in English language from 2015 to 2020-09-15. Results: Bisphosphonates depicted remarkable advantages in improving SREs, skeletal morbidity rate (SMR), survival rate, and treatment-emergent adverse events in breast cancer patients in almost all aspects of breast cancer therapy, from adjuvant therapy for the early stage breast cancer to bone metastatic breast cancer (BMBC). The identification of breast cancer biomarkers that are capable of reflecting the outcomes of bisphosphonates therapy is a highly advantageous aid in the optimal utilization of these drugs. Breast cancer biomarkers such as MAF, DOCK4, CD73, TLR9, and CAPG/GIPC1 composite illustrated a significant correlation with bisphosphonates administration. Medication-related osteonecrosis of the jaw (MRONJ) stands out as the most hazardous adverse event of the bisphosphonates with a rationally high incidence among breast cancer patients, which requires cautious prescription of bisphosphonates as well as regular dental health counseling for being prevented. Conclusions: Bisphosphonates are great weapons in the arsenal of breast cancer treatment and, therefore, comprehensive studying of their features leads to the optimal and safe administration of them. Unfortunately, as this procedure can cause necrosis of the jaw, dental procedures should be performed in these patients before starting bisphosphonate treatment.

show abstract

“…Suarez-Almazor et al recently reported that the administration of the recommended dose of bisphosphonates for OP in postmenopausal women older than 66 years old with breast cancer increase both overall survival and breast-cancer-specific survival after multiple adjustments [ 216 ]. The same year, van Hellemond et al observed no effect of 3 or 6 years bisphosphonates administration before 2 to 3 years of tamoxifen treatment on postmenopausal women distant recurrence free survival, compared with women who did not receive bisphosphonates [ 217 ]. More recently, Perrone et al observed benefits in disease-free survival in premenopausal women undergoing ovarian function suppression treated with adjuvant bisphosphonates compared with women who did not receive adjuvant bisphosphonates [ 218 ].…”

Section: Drugs Commonly Prescribed For Osteoporosis or Rheumatoid mentioning

confidence: 99%

Breast Cancer and Microcalcifications: An Osteoimmunological Disorder?

Clemenceau

Michou

Diorio

et al. 2020

IJMS

View full text Add to dashboard Cite

The presence of microcalcifications in the breast microenvironment, combined with the growing evidences of the possible presence of osteoblast-like or osteoclast-like cells in the breast, suggest the existence of active processes of calcification in the breast tissue during a woman’s life. Furthermore, much evidence that osteoimmunological disorders, such as osteoarthritis, rheumatoid arthritis, or periodontitis influence the risk of developing breast cancer in women exists and vice versa. Antiresorptive drugs benefits on breast cancer incidence and progression have been reported in the past decades. More recently, biological agents targeting pro-inflammatory cytokines used against rheumatoid arthritis also demonstrated benefits against breast cancer cell lines proliferation, viability, and migratory abilities, both in vitro and in vivo in xenografted mice. Hence, it is tempting to hypothesize that breast carcinogenesis should be considered as a potential osteoimmunological disorder. In this review, we compare microenvironments and molecular characteristics in the most frequent osteoimmunological disorders with major events occurring in a woman’s breast during her lifetime. We also highlight what the use of bone anabolic drugs, antiresorptive, and biological agents targeting pro-inflammatory cytokines against breast cancer can teach us.

show abstract

Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial

Cited by 5 publications

References 31 publications

Osteoporosis/Osteopenia in Post-Menopausal Breast Cancer Patients Receiving Hormonal Therapy

Osteoporosis/Osteopenia in Post-Menopausal Breast Cancer Patients Receiving Hormonal Therapy

A Review of Literature on Updates of Bisphosphonates Administration, Cancer Biomarkers for Bisphosphonate Therapy, and Bisphosphonate-related Osteonecrosis of the Jaw in Breast Cancer

Breast Cancer and Microcalcifications: An Osteoimmunological Disorder?

Contact Info

Product

Resources

About